Cargando…

Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens

A major challenge in HIV vaccine development is the identification of immunogens able to elicit broadly neutralizing antibodies (bNAbs). While remarkable progress has been made in the isolation and characterization of bNAbs, the epitopes they recognize appear to be poorly immunogenic. Thus, none of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mesa, Kathryn A., Yu, Bin, Wrin, Terri, Petropoulos, Christos J., Pogson, Grant H., Alexander, David L., Perez, Gerardo, O’Rourke, Sara M., Sinangil, Faruk, Robinson, Joseph, Conant, Marcus A., Berman, Phillip W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457492/ https://www.ncbi.nlm.nih.gov/pubmed/30969970 http://dx.doi.org/10.1371/journal.pone.0213409

Ejemplares similares

P05-14 LB. Analysis of virus swarms to identify vaccine immunogens with improved exposure of epitopes recognized by broadly neutralizing antibodies
por: Berman, P, et al.
Publicado: (2009)

Comparative Immunogenicity of HIV-1 Clade C Envelope Proteins for Prime/Boost Studies
por: Smith, Douglas H., et al.
Publicado: (2010)

Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies
por: Hutchinson, Jennie M., et al.
Publicado: (2019)

Mapping epitopes on CRF01_AE viruses recognized by broadly neutralizing antibodies in sera from elite neutralizers from North America and Thailand
por: O'Rourke, SM, et al.
Publicado: (2012)

Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method
por: Evans, Mark C, et al.
Publicado: (2014)

Glycans Flanking the Hypervariable Connecting Peptide between the A and B Strands of the V1/V2 Domain of HIV-1 gp120 Confer Resistance to Antibodies That Neutralize CRF01_AE Viruses
por: O’Rourke, Sara M., et al.
Publicado: (2015)

Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies
por: Doran, Rachel C., et al.
Publicado: (2018)

Mutations in the V1 domain of Thai CRF01-AE viruses that confer sensitivity/resistance to broadly neutralizing antibodies
por: O'Rourke, S, et al.
Publicado: (2012)

P04-47. High-titer autologous and heterologous neutralizing antibody activity in acute SIV-infection
por: Schweighardt, B, et al.
Publicado: (2009)

Broad Antibody Mediated Cross-Neutralization and Preclinical Immunogenicity of New Codon-Optimized HIV-1 Clade CRF02_AG and G Primary Isolates
por: Agwale, Simon M., et al.
Publicado: (2011)

Novel vomputational methods for predicting epitopes of potent and broadly neutralizing HIV-1 antibodies
por: Evans, MC, et al.
Publicado: (2012)

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
por: McCoy, Laura E., et al.
Publicado: (2015)

Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses
por: Yi, Guohua, et al.
Publicado: (2013)

Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
por: Landais, Elise, et al.
Publicado: (2018)

Accuracy of ancestral state reconstruction for non-neutral traits
por: Holland, Barbara R., et al.
Publicado: (2020)

Development of a Stable MGAT1(−) CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies
por: Doran, Rachel C., et al.
Publicado: (2018)

Correction: Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses
por: Yi, Guohua, et al.
Publicado: (2013)

Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer
por: van Schooten, Jelle, et al.
Publicado: (2022)

Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody
por: Halstead, SB, et al.
Publicado: (1977)

Soluble HIV-1 Envelope Immunogens Derived from an Elite Neutralizer Elicit Cross-Reactive V1V2 Antibodies and Low Potency Neutralizing Antibodies
por: Carbonetti, Sara, et al.
Publicado: (2014)

Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
por: Vanshylla, Kanika, et al.
Publicado: (2022)

Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens
por: Li, Sophia W., et al.
Publicado: (2020)

Elite control of HIV infection: implications for vaccines
por: Pereyra, Florencia, et al.
Publicado: (2006)

Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies
por: Krumm, Stefanie A., et al.
Publicado: (2016)

Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials
por: Yu, Bin, et al.
Publicado: (2012)

Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers
por: Schorcht, Anna, et al.
Publicado: (2020)

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes
por: Hioe, Catarina E., et al.
Publicado: (2010)

Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals
por: Markmann, Alena J., et al.
Publicado: (2021)

Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals
por: Markmann, Alena J., et al.
Publicado: (2021)

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms
por: Buck, Amanda M., et al.
Publicado: (2023)

Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2
por: Williams, Erin, et al.
Publicado: (2022)

Broad neutralization coverage of HIV by multiple highly potent antibodies
por: Walker, Laura M., et al.
Publicado: (2011)

Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies
por: Kim, Soohyun, et al.
Publicado: (2022)

Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies
por: Briney, Bryan, et al.
Publicado: (2016)

Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller
por: Ringel, Oliver, et al.
Publicado: (2018)

HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds
por: van den Kerkhof, Tom L. G. M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2cdspvh46e10v4f4rr53mu4l19